---

---

---

Twitter :

#ConversationsOnCancer

#OCEProjectCommunity

#OCEPFDD

Sponsored by the U.S. Food & Drug Administration (FDA)

Featured Speakers:

Ethan Basch, MD, MSc, Richard M. Goldberg Distinguished Professor in Medical Oncology | Professor of Public Health, Health Policy and Management, Gillings School of Global Public Health | Director, Cancer Outcomes Research Program | Chief of Oncology, University of North Carolina-Chapel Hill |  Physician-in-Chief, North Carolina Cancer Hospital

Jill Feldman, Patient Advocate | Co-Founder of EGFR Resisters 

Erica Horodniceanu, MPH, Health Scientist, Patient Focused Drug Development | Oncology Center of Excellence, FDA 

Lee Jones, Patient Advocate 

Anne Loeser,  Patient Advocate, Author of the Insider's Guide to Metastatic Breast Cancer,  Founder - Patient-Centered Dosing Initiative , Individual Member - Metastatic Breast Cancer Alliance

Dr. Richard Pazdur, MD, Director, Oncology Center of Excellence, FDA

Dr. Mirat Shah, MD, Medical Oncologist and Clinical Reviewer | Office of Oncologic Diseases, Center for Drug Evaluation and Research, FDA

Moderator: Rea Blakey, Associate Director for External Outreach and Engagement, Oncology Center of Excellence, FDA

Registration required to attend: https://www.surveymonkey.com/r/03102022

Background:

The FDA Oncology Center of Excellence (OCE) Conversations on Cancer public panel discussion series event on March 10, 2022 will address understanding tolerability in the context of current cancer treatments. This panel discussion will feature a diverse group of speakers, including patients, clinicians, researchers, and FDA representatives to share their unique perspectives. The speakers will discuss the importance and integration of the patient experience in evaluating tolerability (for example, through use of patient-reported outcome measures), clinician consideration of patient-reported tolerability, the impact of tolerability on treatment decisions, and dose optimization. Registration for this event is free and open to the public.

Webcast Information:

A free-of-charge webcast of this public panel discussion will be provided. Registration for the webcast is required at the link above.

FDA plans to post archived webcasts after the meeting. However, in cases where the transmission was not successful, archived webcasts will not be available.

Contact:

For any inquiries regarding this program, please send an email to:[email protected]